• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Nadofaragene firadenovec and the future of NMIBC care

Video

Dr. Vikram M. Narayan describes treatment advances and next steps in non-muscle invasive bladder cancer.

Vikram M. Narayan, MD, of Emory University, Winship Cancer Institute, Atlanta, GA, discusses next steps with the novel intravesical gene-mediated therapy nadofaragene firadenovec and the overall future of the treatment paradigm for patients with non-muscle invasive bladder cancer (NMIBC).

Narayan says there are promising options, such as nadofaragene firadenovec, emerging for patients with BCG-unresponsive NMIBC. Some of the next steps, according to Narayan, are exploring combination regimens, assessing sequencing strategies, and developing biomarkers to determine which patients might respond best to treatments.

Related Videos
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Gary D. Steinberg, MD, an expert on bladder cancer
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Video 2 - "Exploring Treatments for BCG-Unresponsive Intermediate-High Risk NMIBC"
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Video 1 "Unmet Needs & Standard of Care for Intermediate-High Risk NMIBC"
Related Content
© 2024 MJH Life Sciences

All rights reserved.